Ajanta Pharma

Ajanta Pharma Ltd on Tuesday reported a 18.4 per cent rise in consolidated net profit at Rs 266.7 crore in the fourth quarter ended March 31, on the back of strong US generics revenue growth. The company had posted a consolidated net profit of Rs 225.26 crore in the corresponding period previous fiscal, Ajanta Pharma Ltd said in a regulatory filing. Consolidated revenue from operations in the fourth quarter stood at Rs 1,421.64 crore as against Rs 1,170.41 crore in the year-ago period, it added. During the quarter branded generics in the markets of India, Asia and Africa clocked a combined revenue of Rs 859 crore as compared to Rs 805 crore in the year-ago period, up 7 per cent. US generic revenue was at Rs 505 crore as compared to Rs 325 crore in the same period a year ago, up 56 per cent, the company said. Total expenses in the fourth quarter were higher at Rs 1,135.96 crore as compared to Rs 919.11 crore in the same period a year ago, the company said. For FY26, consolidated n

Coal India, IDBI Bank, Jindal Stainless, Ajanta Pharma and Graphite India were seen trading above the higher end of the Bollinger Bands backed by strong volume on charts.

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

According to PL Capital, Ajanta Pharma's strong franchise will aid in garnering a higher market share for semaglutide

Ajanta Pharma, JBMA Auto and Manappuram Finance have seen strong price action backed by heavy trading volume in Wednesday's trading session.

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Ajanta Pharma has signed an in-licensing pact with Biocon to market semaglutide across 26 countries in Africa, the Middle East and Central Asia, subject to approvals

Pain management, dermatology, nephrology and gynaecology are emerging as key focus areas

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth

The dividend, the company said, will be paid on or after November 20, 2025

The brokerage analysis suggested that branded generics contributed to 74 per cent of Ajanta Pharma's revenue in FY25 and its branded generics business operates with a healthy OPM of 30 per cent

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Looking for the best stocks to buy today? Incred Equities has released its top stock picks for June 2025, recommending 21 stocks to 'Add' across largecap, midcap, and smallcap segments

Indus Towers, Godrej Agrovet, Phoenix Mills, Ajanta Pharma and Star Health stocks dropped up to 12% in intra-day deals on Friday; here are the key levels to track on these 5 stocks.

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Ajanta Pharma on Thursday said its consolidated profit after tax increased by 11 per cent on-year to Rs 233 crore for the third quarter ended December 31, 2024. The drug firm had reported a profit after tax (PAT) of Rs 210 crore in the October-December period of last fiscal. Revenue from operations stood at Rs 1,146 crore in the third quarter compared to Rs 1,105 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. Shares of the company settled 1.64 per cent higher at Rs 2,670.70 apiece on the BSE.

The uptick comes ahead of the company's ex-dividend date tomorrow, driven by its recent dividend announcement that promises rewards for eligible shareholders

Q1 earnings cheer: Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Aurobindo Pharma, Torrent Pharmaceuticals and Sun Pharmaceutical were up between 2 per cent and 3 per cent.

Ajanta Pharma on Tuesday said its consolidated profit after tax (PAT) increased 18 per cent year-on-year to Rs 246 crore for the June quarter, on account of robust sales across domestic and international markets. The drug firm had reported a profit after tax of Rs 208 crore in the April-June quarter of last fiscal. Revenue from operations rose to Rs 1,145 crore during the quarter under review as against Rs 1,021 crore in the year-go period, Ajanta Pharma said in a regulatory filing. The company said its India sales grew 10 per cent year-on-year to Rs 353 crore in the first quarter. The company's US sales grew 7 per cent to Rs 228 crore in the first quarter of the current fiscal. Shares of Ajanta Pharma ended 3.99 per cent up at Rs 2,524.35 apiece on the BSE.